Cargando…
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
Novel therapies are urgently needed to prevent and treat tyrosine kinase inhibitor resistance in chronic myeloid leukaemia (CML). MLN8237 is a novel Aurora A kinase inhibitor under investigation in multiple phase I and II studies. Here we report that MLN8237 possessed equipotent activity against Ba/...
Autores principales: | Kelly, Kevin R, Ecsedy, Jeffrey, Medina, Ernest, Mahalingam, Devalingam, Padmanabhan, Swaminathan, Nawrocki, Steffan T, Giles, Francis J, Carew, Jennifer S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394217/ https://www.ncbi.nlm.nih.gov/pubmed/21091633 http://dx.doi.org/10.1111/j.1582-4934.2010.01218.x |
Ejemplares similares
-
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
por: Swords, Ronan, et al.
Publicado: (2009) -
MLN8054 and Alisertib (MLN8237): Discovery of Selective
Oral Aurora A Inhibitors
por: Sells, Todd B., et al.
Publicado: (2015) -
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
por: Falchook, Gerald S., et al.
Publicado: (2015) -
Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
por: Kelly, Kevin R., et al.
Publicado: (2013) -
MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas
por: Nair, Jayasree S., et al.
Publicado: (2016)